1,091 research outputs found

    How to read a next-generation sequencing report-what oncologists need to know.

    Get PDF
    Next-generation sequencing (NGS) of tumor cell-derived DNA/RNA to screen for targetable genomic alterations is now widely available and has become part of routine practice in oncology. NGS testing strategies depend on cancer type, disease stage and the impact of results on treatment selection. The European Society for Medical Oncology (ESMO) has recently published recommendations for the use of NGS in patients with advanced cancer. We complement the ESMO recommendations with a practical review of how oncologists should read and interpret NGS reports. A concise and straightforward NGS report contains details of the tumor sample, the technology used and highlights not only the most important and potentially actionable results, but also other pathogenic alterations detected. Variants of unknown significance should also be listed. Interpretation of NGS reports should be a joint effort between molecular pathologists, tumor biologists and clinicians. Rather than relying and acting on the information provided by the NGS report, oncologists need to obtain a basic level of understanding to read and interpret NGS results. Comprehensive annotated databases are available for clinicians to review the information detailed in the NGS report. Molecular tumor boards do not only stimulate debate and exchange, but may also help to interpret challenging reports and to ensure continuing medical education

    Structural and spectroscopic characterization of a HdrA-like subunit from Hyphomicrobium denitrificans

    Get PDF
    Funding Information: We thank Laurenz Heidrich for help with statistical analyses. This work was supported by grant Da 351/8‐1 (to CD) from the Deutsche Forschungsgemeinschaft and Fundação para a CiĂȘncia e Tecnologia (Portugal) (grant PTDC/BIA‐BQM/29118 and R&D units MOSTMICRO‐ITQB (UIDB/04612/2020 and UIDP/04612/2020), and European Union's Horizon 2020 research and innovation program (grant agreement No 810856). Open access funding enabled and organized by Projekt DEAL. Publisher Copyright: © 2020 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies Copyright: Copyright 2021 Elsevier B.V., All rights reserved.Many bacteria and archaea employ a novel pathway of sulfur oxidation involving an enzyme complex that is related to the heterodisulfide reductase (Hdr or HdrABC) of methanogens. As a first step in the biochemical characterization of Hdr-like proteins from sulfur oxidizers (sHdr), we structurally analyzed the recombinant sHdrA protein from the Alphaproteobacterium Hyphomicrobium denitrificans at 1.4 Å resolution. The sHdrA core structure is similar to that of methanogenic HdrA (mHdrA) which binds the electron-bifurcating flavin adenine dinucleotide (FAD), the heart of the HdrABC-[NiFe]-hydrogenase catalyzed reaction. Each sHdrA homodimer carries two FADs and two [4Fe–4S] clusters being linked by electron conductivity. Redox titrations monitored by electron paramagnetic resonance and visible spectroscopy revealed a redox potential between −203 and −188 mV for the [4Fe–4S] center. The potentials for the FADH‱/FADH− and FAD/FADH‱ pairs reside between −174 and −156 mV and between −81 and −19 mV, respectively. The resulting stable semiquinone FADH‱ species already detectable in the visible and electron paramagnetic resonance spectra of the as-isolated state of sHdrA is incompatible with basic principles of flavin-based electron bifurcation such that the sHdr complex does not apply this new mode of energy coupling. The inverted one-electron FAD redox potentials of sHdr and mHdr are clearly reflected in the different FAD-polypeptide interactions. According to this finding and the assumption that the sHdr complex forms an asymmetric HdrAAâ€ČB1C1B2C2 hexamer, we tentatively propose a mechanism that links protein-bound sulfane oxidation to sulfite on HdrB1 with NAD+ reduction via lipoamide disulfide reduction on HdrB2. The FAD of HdrA thereby serves as an electron storage unit. Database: Structural data are available in PDB database under the accession number 6TJR.publishe

    End of life care in sub-Saharan Africa: a systematic review of the qualitative literature

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>End of life (EoL) care in sub-Saharan Africa still lacks the sound evidence-base needed for the development of effective, appropriate service provision. It is essential to make evidence from all types of research available alongside clinical and health service data, to ensure that EoL care is ethical and culturally appropriate. This article aims to synthesize qualitative research on EoL care in sub-Saharan Africa to inform policy, practice and further research. It seeks to identify areas of existing research; describe findings specifically relevant to the African context; and, identify areas lacking evidence.</p> <p>Methods</p> <p>Relevant literature was identified through eight electronic databases: AMED, British Nursing Index & Archive, CINAHL, EMBASE, IBSS, MEDLINE, PsycINFO, and the Social Sciences Citation Index; and hand searches. Inclusion criteria were: published qualitative or mixed-method studies in sub-Saharan Africa, about EoL care. Study quality was assessed using a standard grading scale. Relevant data including findings and practice recommendations were extracted and compared in tabular format.</p> <p>Results</p> <p>Of the 407 articles initially identified, 51 were included in the qualitative synthesis. Nineteen came from South Africa and the majority (38) focused on HIV/AIDS. Nine dealt with multiple or unspecified conditions and four were about cancer. Study respondents included health professionals, informal carers, patients, community members and bereaved relatives. Informal carers were typically women, the elderly and children, providing total care in the home, and lacking support from professionals or the extended family. Twenty studies focused on home-based care, describing how programmes function in practice and what is needed to make them effective. Patients and carers were reported to prefer institutional care but this needs to be understood in context. Studies focusing on culture discussed good and bad death, culture-specific approaches to symptoms and illness, and the bereavement process.</p> <p>Conclusions</p> <p>The data support or complement the findings from quantitative research. The review prompts a reconsideration of the assumption that in Africa the extended family care for the sick, and that people prefer home-based care. The review identifies areas relevant for a research agenda on socio-cultural issues at the EoL in sub-Saharan Africa.</p

    Evaluation of the effectiveness of music therapy in improving the quality of life of palliative care patients: a randomised controlled pilot and feasibility study.

    Get PDF
    BACKGROUND: Music therapy is frequently used as a palliative therapy. In consonance with the goals of palliative care, the primary aim of music therapy is to improve people's quality of life by addressing their psychological needs and facilitating communication. To date, primarily because of a paucity of robust research, the evidence for music therapy's effectiveness on patient reported outcomes is positive but weak. This pilot and feasibility study will test procedures, outcomes and validated tools; estimate recruitment and attrition rates; and calculate the sample size required for a phase III randomised trial to evaluate the effectiveness of music therapy in improving the quality of life of palliative care patients. METHODS: A pilot randomised controlled trial supplemented with qualitative methods. The quantitative data collection will involve recruitment of >52 patients from an inpatient Marie Curie hospice setting over a 12-month period. Eligibility criteria include all patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 03- indicating they are medically fit to engage with music therapy and an Abbreviated Mental Test (AMT) score of ≄7 indicating they are capable of providing meaningful informed consent and accurate responses to outcome measures. Baseline data collection will include the McGill Quality of Life Questionnaire (MQOL); medical and socio-demographic data will be undertaken before randomisation to an intervention or control group. Participants in the intervention arm will be offered two 30-45 min sessions of music therapy per week for three consecutive weeks, in addition to care as usual. Participants in the control arm will receive care as usual. Follow-up measures will be administered in 1, 3 and 5 weeks. Qualitative data collection will involve focus group and individual interviews with HCPs and carers. DISCUSSION: This study will ensure a firm methodological grounding for the development of a robust phase III randomised trial of music therapy for improving quality of life in palliative care patients. By undertaking the pilot and feasibility trial under normal clinical conditions in a hospice setting, the trial will result in reliable procedures to overcome some of the difficulties in designing music therapy RCTs for palliative care settings. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT02791048

    Đ€ĐžĐ·ĐžĐŸĐ»ĐŸĐłĐžŃ‡Đ”ŃĐșĐŸĐ” ĐŸĐ±ĐŸŃĐœĐŸĐČĐ°ĐœĐžĐ” Ń‚Ń€Đ”ĐœĐžŃ€ĐŸĐČĐșĐž плДчДĐČĐŸĐłĐŸ ĐżĐŸŃŃĐ° у ĐżĐ»ĐŸĐČŃ†ĐŸĐČ ĐœĐ° ŃŃ‚Đ°ĐżĐ” ŃĐżĐŸŃ€Ń‚ĐžĐČĐœĐŸĐłĐŸ ŃĐŸĐČĐ”Ń€ŃˆĐ”ĐœŃŃ‚ĐČĐŸĐČĐ°ĐœĐžŃ

    Get PDF
    В плаĐČĐ°ĐœĐžĐž, Ń€Đ°Đ±ĐŸŃ‚Đ° плДчДĐČĐŸĐłĐŸ ĐżĐŸŃŃĐ° яĐČĐ»ŃĐ”Ń‚ŃŃ ĐŽĐŸŃŃ‚Đ°Ń‚ĐŸŃ‡ĐœĐŸ Đ°ĐșŃ‚ŃƒĐ°Đ»ŃŒĐœĐŸĐč Ń‚Đ”ĐŒĐŸĐč, таĐș ĐșĐ°Đș ĐœĐ°Đ±Đ»ŃŽĐŽĐ°Đ”Ń‚ŃŃ Đ·ĐœĐ°Ń‡ĐžŃ‚Đ”Đ»ŃŒĐœĐŸĐ” ĐżŃ€Đ”ĐŸĐ±Đ»Đ°ĐŽĐ°ĐœĐžĐ” ŃƒŃ€ĐŸĐČĐœŃ фОзОчДсĐșĐŸĐč ĐżĐŸĐŽĐłĐŸŃ‚ĐŸĐČĐ»Đ”ĐœĐœĐŸŃŃ‚Đž Đ·Đ°ĐœĐžĐŒĐ°ŃŽŃ‰ĐžŃ…ŃŃ ĐșĐŸŃ‚ĐŸŃ€Ń‹Đ” ĐžŃĐżĐŸĐ»ŃŒĐ·ŃƒŃŽŃ‚ Ń‚Ń€Đ”ĐœĐžŃ€ĐŸĐČĐŸŃ‡ĐœŃƒŃŽ ĐœĐ°ĐłŃ€ŃƒĐ·Đșу ĐœĐ° плДчДĐČĐŸĐč ĐżĐŸŃŃ, ĐœĐ°ĐŽ Ń‚Đ”ĐŒĐž ĐșŃ‚ĐŸ ĐŒĐ°Đ»ĐŸ ŃƒĐŽĐ”Đ»ŃĐ”Ń‚ ŃŃ‚ĐŸĐŒŃƒ ĐČĐœĐžĐŒĐ°ĐœĐžŃ, Ń‡Ń‚ĐŸ ĐœĐ” ЎаДт ĐżĐŸ ĐŸĐ±Ń‰Đ”ĐŒŃƒ ŃŃ‡Đ”Ń‚Ńƒ ĐČĐŸĐ·ĐŒĐŸĐ¶ĐœĐŸŃŃ‚Đž ŃĐŸĐČĐ”Ń€ŃˆĐ”ĐœŃŃ‚ĐČĐŸĐČаться ĐČ ĐŽĐ°ĐœĐœĐŸĐč спДцОалОзацОО, ĐŸŃĐŸĐ±Đ”ĐœĐœĐŸ ĐœĐ° этапах ŃĐżĐŸŃ€Ń‚ĐžĐČĐœĐŸĐłĐŸ ŃĐŸĐČĐ”Ń€ŃˆĐ”ĐœŃŃ‚ĐČĐŸĐČĐ°ĐœĐžŃ.In swimming, the work of the shoulder girdle is quite an actual topic, since there is a significant predominance of the level of physical fitness of those engaged in that use the training load on the shoulder girdle, over those who pay little attention to it, which does not give an opportunity to improve in this specialization, Stages of sports improvement

    Measurement of the mass and lifetime of the Ωb−\Omega_b^- baryon

    Get PDF
    A proton-proton collision data sample, corresponding to an integrated luminosity of 3 fb−1^{-1} collected by LHCb at s=7\sqrt{s}=7 and 8 TeV, is used to reconstruct 63±963\pm9 Ωb−→Ωc0π−\Omega_b^-\to\Omega_c^0\pi^-, Ωc0→pK−K−π+\Omega_c^0\to pK^-K^-\pi^+ decays. Using the Ξb−→Ξc0π−\Xi_b^-\to\Xi_c^0\pi^-, Ξc0→pK−K−π+\Xi_c^0\to pK^-K^-\pi^+ decay mode for calibration, the lifetime ratio and absolute lifetime of the Ωb−\Omega_b^- baryon are measured to be \begin{align*} \frac{\tau_{\Omega_b^-}}{\tau_{\Xi_b^-}} &= 1.11\pm0.16\pm0.03, \\ \tau_{\Omega_b^-} &= 1.78\pm0.26\pm0.05\pm0.06~{\rm ps}, \end{align*} where the uncertainties are statistical, systematic and from the calibration mode (for τΩb−\tau_{\Omega_b^-} only). A measurement is also made of the mass difference, mΩb−−mΞb−m_{\Omega_b^-}-m_{\Xi_b^-}, and the corresponding Ωb−\Omega_b^- mass, which yields \begin{align*} m_{\Omega_b^-}-m_{\Xi_b^-} &= 247.4\pm3.2\pm0.5~{\rm MeV}/c^2, \\ m_{\Omega_b^-} &= 6045.1\pm3.2\pm 0.5\pm0.6~{\rm MeV}/c^2. \end{align*} These results are consistent with previous measurements.Comment: 11 pages, 5 figures, All figures and tables, along with any supplementary material and additional information, are available at https://lhcbproject.web.cern.ch/lhcbproject/Publications/LHCbProjectPublic/LHCb-PAPER-2016-008.htm

    Measurement of the Bs0→J/ψηB_{s}^{0} \rightarrow J/\psi \eta lifetime

    Get PDF
    Using a data set corresponding to an integrated luminosity of 3fb−13 fb^{-1}, collected by the LHCb experiment in pppp collisions at centre-of-mass energies of 7 and 8 TeV, the effective lifetime in the Bs0→J/ψηB^0_s \rightarrow J/\psi \eta decay mode, τeff\tau_{\textrm{eff}}, is measured to be τeff=1.479±0.034 (stat)±0.011 (syst)\tau_{\textrm{eff}} = 1.479 \pm 0.034~\textrm{(stat)} \pm 0.011 ~\textrm{(syst)} ps. Assuming CPCP conservation, τeff\tau_{\textrm{eff}} corresponds to the lifetime of the light Bs0B_s^0 mass eigenstate. This is the first measurement of the effective lifetime in this decay mode.Comment: All figures and tables, along with any supplementary material and additional information, are available at https://lhcbproject.web.cern.ch/lhcbproject/Publications/LHCbProjectPublic/LHCb-PAPER-2016-017.htm

    Search for the rare decays B0→J/ÏˆÎłB^{0}\to J/\psi \gamma and Bs0→J/ÏˆÎłB^{0}_{s} \to J/\psi \gamma

    Get PDF
    A search for the rare decay of a B0B^{0} or Bs0B^{0}_{s} meson into the final state J/ÏˆÎłJ/\psi\gamma is performed, using data collected by the LHCb experiment in pppp collisions at s=7\sqrt{s}=7 and 88 TeV, corresponding to an integrated luminosity of 3 fb−1^{-1}. The observed number of signal candidates is consistent with a background-only hypothesis. Branching fraction values larger than 1.7×10−61.7\times 10^{-6} for the B0→J/ÏˆÎłB^{0}\to J/\psi\gamma decay mode are excluded at 90% confidence level. For the Bs0→J/ÏˆÎłB^{0}_{s}\to J/\psi\gamma decay mode, branching fraction values larger than 7.4×10−67.4\times 10^{-6} are excluded at 90% confidence level, this is the first branching fraction limit for this decay.Comment: All figures and tables, along with any supplementary material and additional information, are available at https://lhcbproject.web.cern.ch/lhcbproject/Publications/LHCbProjectPublic/LHCb-PAPER-2015-044.htm

    Observation of an Excited Bc+ State

    Get PDF
    Using pp collision data corresponding to an integrated luminosity of 8.5 fb-1 recorded by the LHCb experiment at center-of-mass energies of s=7, 8, and 13 TeV, the observation of an excited Bc+ state in the Bc+π+π- invariant-mass spectrum is reported. The observed peak has a mass of 6841.2±0.6(stat)±0.1(syst)±0.8(Bc+) MeV/c2, where the last uncertainty is due to the limited knowledge of the Bc+ mass. It is consistent with expectations of the Bc∗(2S31)+ state reconstructed without the low-energy photon from the Bc∗(1S31)+→Bc+Îł decay following Bc∗(2S31)+→Bc∗(1S31)+π+π-. A second state is seen with a global (local) statistical significance of 2.2σ (3.2σ) and a mass of 6872.1±1.3(stat)±0.1(syst)±0.8(Bc+) MeV/c2, and is consistent with the Bc(2S10)+ state. These mass measurements are the most precise to date

    Observation of J/ψpJ/\psi p resonances consistent with pentaquark states in Λb0→J/ψK−p{\Lambda_b^0\to J/\psi K^-p} decays

    Get PDF
    Observations of exotic structures in the J/ψpJ/\psi p channel, that we refer to as pentaquark-charmonium states, in Λb0→J/ψK−p\Lambda_b^0\to J/\psi K^- p decays are presented. The data sample corresponds to an integrated luminosity of 3/fb acquired with the LHCb detector from 7 and 8 TeV pp collisions. An amplitude analysis is performed on the three-body final-state that reproduces the two-body mass and angular distributions. To obtain a satisfactory fit of the structures seen in the J/ψpJ/\psi p mass spectrum, it is necessary to include two Breit-Wigner amplitudes that each describe a resonant state. The significance of each of these resonances is more than 9 standard deviations. One has a mass of 4380±8±294380\pm 8\pm 29 MeV and a width of 205±18±86205\pm 18\pm 86 MeV, while the second is narrower, with a mass of 4449.8±1.7±2.54449.8\pm 1.7\pm 2.5 MeV and a width of 39±5±1939\pm 5\pm 19 MeV. The preferred JPJ^P assignments are of opposite parity, with one state having spin 3/2 and the other 5/2.Comment: 48 pages, 18 figures including the supplementary material, v2 after referee's comments, now 19 figure
    • 

    corecore